ENDOCRINE THERAPY DRUGS (ETDS) MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

The endocrine system of the human body uses hormones to control and coordinate with the human body’s metabolism, reproduction, energy level, growth and development, as well as response for stress, injury, and mood disorders. Endocrine therapy, also known as hormone therapy, adds, blocks, or removes hormones/chemicals in order to treat diseases such as breast cancer, diabetes, etc. Estrogen and progesterone found in a woman’s body can aggravate breast cancer as these hormones help the cells grow and spread throughout the body. Two types of endocrine therapy can be used for the treatment of breast cancer, i.e. a) blocking the action of estrogen and progesterone to stop them from helping cancerous cells to grow and, b) using drugs or surgery to stop the ovary from producing estrogen and progesterone. Some of the endocrine therapy drugs used in breast cancer treatment include Abemaciclib (Verzenio), Anastrozole (Arimidex), Exemestane (Aromasin), and Fulvestrant (Faslodex), among others.

Market Dynamics

The increasing prevalence of chronic diseases such as diabetes, breast cancer, and others, rising research and development activities to develop novel endocrine therapy drugs (ETDs), and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global endocrine therapy drugs (ETDs) market over the forecast period.

For instance, according to the International Federation of Diabetes Atlas 2019, around 463 million people aged 20-79 years and 136 million people aged 65 are estimated to be suffering from diabetes in 2019, globally. Moreover, according to the International Diabetes Federation Diabetes Atlas 2019, the prevalence of diabetes in Costa Rica is predicted to increase form 9.1 in 2019 to 10.3 by 2030.

Key features of the study:

• This report provides an in-depth analysis of the global endocrine therapy drugs (ETDs) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global endocrine therapy drugs (ETDs) market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Novo Nordisk A/S, AstraZeneca, Generex Biotechnology, Orion Pharma AB, Sanofi, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Hisamitsu Pharmaceutical Co.,Inc., Bayer AG, Eli Lilly and Company, Abbott, Tonghua Dongbao Pharmaceutical Co., Ltd., Merck & Co., Inc., TherapeuticsMD, Inc., Pfizer Inc., Allergan, BioSante Pharmaceuticals, Amgen Inc., Noven Pharmaceuticals, Inc., and QuatRx Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global endocrine therapy drugs (ETDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global endocrine therapy drugs (ETDs) market

Detailed Segmentation:

• Global Endocrine Therapy Drugs (ETDs) Market, By Drug Type:
  • Anti-diabetic Drugs
  • Anti-osteoporosis Drugs
  • Contraceptive Drugs
  • Breast Cancer Drugs
  • Others (Menopause Drugs, among others)
• Global Endocrine Therapy Drugs (ETDs) Market, By Application:
  • Diabetes
  • Breast Cancer
  • Osteoporosis
  • Menopause
  • Contraception
  • Others (Gender Reassignment Surgery, Hypothyroidism, among others)
• Global Endocrine Therapy Drugs (ETDs) Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Endocrine Therapy Drugs (ETDs) Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Novo Nordisk A/S*
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • AstraZeneca
  • Generex Biotechnology
  • Orion Pharma AB
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Hoffmann-La Roche
  • Hisamitsu Pharmaceutical Co.,Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Abbott
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • TherapeuticsMD, Inc.
  • Pfizer Inc.
  • Allergan
  • BioSante Pharmaceuticals
  • Amgen Inc.
  • Noven Pharmaceuticals, Inc.
  • QuatRx Pharmaceuticals

 “*” marked represents similar segmentation in other categories in the respective section.